ERBB2 and breast neoplasm: Enhertu® is another approved ADC targeted to HER-2 receptors that consists of trastuzumab bound to deruxtecan through an enzymatically cleavable linker [51] and that has been approved in the last two years by the FDA and EMA for the treatment of unresectable metastatic HER-2-positive breast tumors [52].